SecBot SecBot

ADMA

ADMA BIOLOGICS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001368514 Biotech & Drug Discovery
$10.68 −0.27 (−2.47%)
Oct 23 4:00 PM ET · prev $10.95
Market cap
$2.5B
Mid cap
Median target
🔒 Subscribers only
1 year
−29.6%
from $15.18 · Oct 24
30 days
+12.2%
from $9.52
52-week range
$7.60–20.38
−48% from high · low Jun 2
Avg volume 20D
2.95M
shares / day
Short interest
20.60M
≈9.2% of shares · −14.9%
Days to cover
5.7
at average volume
Insider net
-$345.5K
2 buyers · 2 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 1 exit
Reddit crowd
50°
Neutral · 1 mention this week
Filing reports
5
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine detailing data…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    2 insiders bought $468.3K at an average $10.31. 2 insiders sold $813.8K.

  • InstitutionsMIXED

    Q2 2026: 31 added (1 new), 38 trimmed or exited. Largest new: Life Cycle Investment Partners $12.7M.

  • Short sellersSTEADY

    Short interest −14.9% to 20.60M shares. 5.7 days to cover, ≈9.2% of shares.

  • TrendUPTREND

    9% above its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
1
new positions
1
exit
$12.7M
in new stakes
FundMoveSharesValue
Rubric Capital Management LPDOUBLED9,339,414$78.2M
FIRST TRUST ADVISORS LPDOUBLED7,798,351$65.3M
D. E. Shaw & Co., Inc.DOUBLED5,274,597$44.1M
DIMENSIONAL FUND ADVISORS LPTRIM3,606,208$30.2M
GOLDMAN SACHS GROUP INCADD3,513,583$29.4M
Nuveen, LLCTRIM3,260,349$27.3M
Duquesne Family Office LLCADD2,784,110$23.3M
BANK OF AMERICA CORP /DE/TRIM1,647,647$13.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jul 15, 2026Mizuho
MAINTAIN
MAINTAINOutperform
May 7, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
May 7, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
r/wallstreetbets Neutral 5d ago
New Portfolio: EST 30-35% YoY Return (3-5 year forecast ~160%)
1 upvotes · 0 comments
All social signals and their track records

Insider ledger

Form 4
$468.3K
bought · 2 insiders
$813.8K
sold · 2 insiders
+3.5%
vs their $10.31 cost
DateInsiderTypeValue
Jul 24, 2026
Kestenberg-Messina Kaitlin M.
COO and SVP, Compliance
TAX W/H$26.6K
Jul 16, 2026
Kohler Terry
CFO and Treasurer
AWARD136,363 sh
Jul 16, 2026
Kohler Terry
CFO and Treasurer
AWARD85,130 sh
May 27, 2026
Grossman Jerrold B
Director
BUY$50.6K
May 12, 2026
Grossman Jerrold B
Director
BUY$100.1K
May 11, 2026
Grossman Jerrold B
Director
BUY$100.1K
Apr 1, 2026
Kestenberg-Messina Kaitlin M.
COO and SVP, Compliance
TAX W/H$185.5K
Mar 17, 2026
Guiheen Lawrence P.
Director
GIFT30,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
20,597,867
shares short
-14.9%
vs prior settlement
5.7
days to cover
≈9.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Press
ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine detailing data from its…
Impact 4/10
Oct 15, 2026 FDA
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immuno
Aug 8, 2026 SEC
A mixed institutional cluster in ADMA BIOLOGICS for 2026-Q2 shows 5 buyers accumulating $4.5M in net new positions…
INST-CLUSTER — Impact 4/10
Jul 24, 2026 Insider
Kestenberg-Messina Kaitlin M. surrendered for taxes 3,177 shares
COO and SVP, Compliance @ $8.37 ($26.6K)
Jul 16, 2026 Insider
Kohler Terry was granted 136,363 shares
CFO and Treasurer
Jul 16, 2026 Insider
Kohler Terry was granted 85,130 shares
CFO and Treasurer
Jun 30, 2026 Inst.
Rubric Capital Management LP — DOUBLED
9,339,414 shares ($78.2M)
Jun 30, 2026 Inst.
FIRST TRUST ADVISORS LP — DOUBLED
7,798,351 shares ($65.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 15, 2026
FDA
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No...
Aug 31, 2026
Press release
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of…
Aug 21, 2026
Press release
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of…
Aug 21, 2026
Press release
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or…
Aug 10, 2026
Press release
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics…

SecBot reports

5 filings · 2 press releases · 2 bullish · 0 bearish · 2 mixed · 1 neutral
All ADMA filing & press-release reports (7)